103 related articles for article (PubMed ID: 1626425)
1. Nucleocapsid specific T and B cell responses in humans after rabies vaccination.
Herzog M; Lafage M; Montaño-Hirose JA; Fritzell C; Scott-Algara D; Lafon M
Virus Res; 1992 Jun; 24(1):77-89. PubMed ID: 1626425
[TBL] [Abstract][Full Text] [Related]
2. Amplification of rabies virus-induced stimulation of human T-cell lines and clones by antigen-specific antibodies.
Celis E; Wiktor TJ; Dietzschold B; Koprowski H
J Virol; 1985 Nov; 56(2):426-33. PubMed ID: 3877176
[TBL] [Abstract][Full Text] [Related]
3. T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination.
Herzog M; Fritzell C; Lafage M; Montaño Hirose JA; Scott-Algara D; Lafon M
Clin Exp Immunol; 1991 Aug; 85(2):224-30. PubMed ID: 1864001
[TBL] [Abstract][Full Text] [Related]
4. Rabies-specific production of interleukin-2 by peripheral blood lymphocytes from human rabies vaccinees.
Perrin P; Joffret ML; Zanetti C; Bourhy H; Gontier C; Fritzell C; Leclerc C; Sureau P
Vaccine; 1991 Aug; 9(8):549-58. PubMed ID: 1771968
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to nucleic acid vaccines to rabies virus.
Xiang ZQ; Spitalnik SL; Cheng J; Erikson J; Wojczyk B; Ertl HC
Virology; 1995 Jun; 209(2):569-79. PubMed ID: 7778289
[TBL] [Abstract][Full Text] [Related]
6. The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays.
Moore SM; Ricke TA; Davis RD; Briggs DJ
Biologicals; 2005 Dec; 33(4):269-76. PubMed ID: 16168666
[TBL] [Abstract][Full Text] [Related]
7. Rabies virus-specific human T cell clones provide help for an in vitro antibody response against neutralizing antibody-inducing determinants of the viral glycoprotein.
Bunschoten H; Klapmuts RJ; Claassen IJ; Reyneveld SD; Osterhaus AD; Uytdehaag FG
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1513-21. PubMed ID: 2471814
[TBL] [Abstract][Full Text] [Related]
8. Detection of cellular immunity to rabies antigens in human vaccinees.
Moore SM; Wilkerson MJ; Davis RD; Wyatt CR; Briggs DJ
J Clin Immunol; 2006 Nov; 26(6):533-45. PubMed ID: 16964551
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cell-mediated immune responses of foxes (Vulpes vulpes) after experimental primary and secondary oral vaccination using SAG2 and V-RG vaccines.
Lambot M; Blasco E; Barrat J; Cliquet F; Brochier B; Renders C; Krafft N; Bailly J; Munier M; Aubert MF; Pastoret PP
Vaccine; 2001 Feb; 19(13-14):1827-35. PubMed ID: 11166908
[TBL] [Abstract][Full Text] [Related]
10. Induction of antigen-specific antibody response in human peripheral blood lymphocytes in vitro by a dog kidney cell vaccine against rabies virus (DKCV).
Uytdehaag FG; Osterhaus AD; Loggen HG; Bakker RH; van Asten JA; Kreeftenberg JG; van der Marel P; van Steenis B
J Immunol; 1983 Sep; 131(3):1234-9. PubMed ID: 6193180
[TBL] [Abstract][Full Text] [Related]
11. Rabies superantigen as a Vbeta T-dependent adjuvant.
Astoul E; Lafage M; Lafon M
J Exp Med; 1996 Apr; 183(4):1623-31. PubMed ID: 8666920
[TBL] [Abstract][Full Text] [Related]
12. Rabies DNA vaccination by the intranasal route in dogs.
Tesoro Cruz E; Hernández González R; Alonso Morales R; Aguilar-Setién A
Dev Biol (Basel); 2006; 125():221-31. PubMed ID: 16878480
[TBL] [Abstract][Full Text] [Related]
13. Human immune response to rabies nucleocapsid and glycoprotein antigens.
Kasempimolporn S; Hemachudha T; Khawplod P; Manatsathit S
Clin Exp Immunol; 1991 May; 84(2):195-9. PubMed ID: 2025949
[TBL] [Abstract][Full Text] [Related]
14. Immune responses of humans to a human diploid cell strain of rabies virus vaccine: lymphocyte transformation, production of virus-neutralizing antibody, and induction of interferon.
Nicholson KG; Cole PJ; Turner GS; Harrison P
J Infect Dis; 1979 Aug; 140(2):176-82. PubMed ID: 479638
[TBL] [Abstract][Full Text] [Related]
15. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals.
Lodmell DL; Esposito JJ; Ewalt LC
Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356
[TBL] [Abstract][Full Text] [Related]
16. Activation of human tonsil lymphocytes by rabies virus nucleocapsid superantigen.
Martinez-Arends A; Astoul E; Lafage M; Lafon M
Clin Immunol Immunopathol; 1995 Nov; 77(2):177-84. PubMed ID: 7586725
[TBL] [Abstract][Full Text] [Related]
17. Rabies ribonucleocapsid as an oral immunogen and immunological enhancer.
Hooper DC; Pierard I; Modelska A; Otvos L; Fu ZF; Koprowski H; Dietzschold B
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):10908-12. PubMed ID: 7971982
[TBL] [Abstract][Full Text] [Related]
18. Cell-mediated immune response to rabies virus in dogs following vaccination and challenge.
Gerber JD; Sharpee RL; Swieczkowski TC; Beckenhauer WH
Vet Immunol Immunopathol; 1985 May; 9(1):13-22. PubMed ID: 4024449
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein.
Fujii H; Takita-Sonoda Y; Mifune K; Hirai K; Nishizono A; Mannen K
J Gen Virol; 1994 Jun; 75 ( Pt 6)():1339-44. PubMed ID: 8207400
[TBL] [Abstract][Full Text] [Related]
20. The influence of the type of immunosorbent on rabies antibody EIA; advantages of purified glycoprotein over whole virus.
Perrin P; Versmisse P; Delagneau JF; Lucas G; Rollin PE; Sureau P
J Biol Stand; 1986 Apr; 14(2):95-102. PubMed ID: 3531213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
